24 results about "Myostatin" patented technology

The invention discloses application of serum MSTN (myostatin) as a marker in preparation of a metabolism-related steatohepatitis diagnosis product, and belongs to the technical field of biomedical detection. The biomarker for noninvasive diagnosis of the metabolism-related steatohepatitis is serum myosostatin MSTN, and the biomarker can be used as a detection target for preparing a noninvasive diagnosis product of the metabolism-related steatohepatitis. As an independent biomarker, the MSTN is higher in diagnosis efficiency in AST normal patients; the MSTN and the ALT or the AST are jointly applied, so that the specificity and the positive predictive value (PPV) of single use of the ALT or the AST can be improved, the misdiagnosis rate of the ALT or the AST can be reduced, non-MASH patients can be more accurately excluded, and unnecessary, invasive or expensive subsequent examinations are reduced.

Aspects of the present disclosure relate to antibodies that specifically bind proMyostatin and / or latent Myostatin and uses thereof.

A novel preventive and / or therapeutic agent useful in the prevention and / or treatment of a disease whose symptom is alleviated or improved by the inhibition of myostatin. The present invention relates to an agent for preventing and / or treating a disease whose symptom is alleviated or improved by the inhibition of myostatin, the agent including a therapeutically effective dose of (R)-2-[3-[[N-(benzoxazol-2-yl)-N-3-(4-methoxyphenoxy)propyl]aminomethyl]phenoxy]butyric acid, a salt thereof, or a solvate thereof.

The present disclosure relates to antibodies and antigen-binding fragments that specifically bind to pro / latent myostatin and uses thereof.

Provided are a double-stranded siRNA analog for inhibiting myostatin (MSTN) expression, a preparation method therefor, and use thereof. The double-stranded siRNA analog can inhibit MSTN expression and be used for preventing and / or treating MSTN-related diseases and disorders, such as myoatrophy.

The present disclosure relates to antibodies and antigen-binding fragments that specifically bind to pro / latent myostatin and uses thereof.

This invention discloses an instant gelling powder of sodium alginate / calcium β-hydroxy-β-methylbutyrate with dual functions of fat reduction and muscle gain, and its application, belonging to the field of functional food or pharmaceutical preparation technology. The powder of this invention is prepared by dry mixing sodium alginate and CaHMB at a weight ratio of 5~10:1~5, preferably 7:3, wherein the guluronic acid content of sodium alginate is ≥50%. In use, 1g of powder is added to 20~40mL of water at 60~100°C, and stirred to form a hydrogel. After oral administration, the powder rapidly forms a gel in the stomach, producing a feeling of fullness, and simultaneously achieves fat reduction, muscle gain, and metabolic regulation functions by regulating myostatin expression. This invention overcomes the limitation of existing weight management products with only one function, innovatively integrating the three major effects of instant satiety, fat reduction, and muscle gain. The preparation process is simple and environmentally friendly, requiring no added chemical excipients, and has significant technological advancement and market application value.

A method for constructing a mouse model for rapid degradation of Myostatin (MSTN) protein is provided. The method includes: inserting sequentially a 5′ homologous arm, 3 X (Glu-Ala-Ala-Ala-Lys) (3xEAAAK), an FK506-binding protein (FKBP1A) gene synonymous mutation sequence, 3xEAAAK, a red fluorescent protein monomeric Cherry (mCherry) sequence and a 3′ homologous arm into a Donor vector backbone to obtain a Donor recombinant vector; designing a Guide Ribonucleic Acid (gRNA) based on a third exon of the Mstn gene; mixing the gRNA, CRISPR-associated protein 9 (Cas9) protein, and the Donor recombinant vector and co-injecting a mixture of the above into mouse fertilized eggs, culturing the fertilized eggs in vitro and transplanting to obtain the F0 generation mice; and hybridizing the F0 generation mice with wild-type mice, or further breeding hybridized offspring to obtain a knock-in mouse model.

The present invention provides stabilized activin IIB receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the stabilized polypeptides and proteins. Compositions and methods for treating muscle-wasting diseases and metabolic disorders are also provided.

The present invention relates to a pharmaceutical composition for preventing or treating muscle diseases. Specifically, the elderberry extract or monosaccharide and amino acid combined compound disclosed by the invention inhibits apoptosis of muscle cells, inhibits expression of inflammatory cytokines, promotes secretion of testosterone and inhibits expression of amyotrophy marker protein and myogenesis inhibition protein, and shows an effect of recovering muscle in a sarcopenia animal model; therefore, the device can be effectively used in the treatment of muscle diseases.

The application discloses a primer set for real-time fluorescent quantitative PCR detection of a pig muscle regulatory factor and application thereof, and belongs to the technical field of biology. The application provides specific primer pairs capable of detecting pig muscle regulatory factors MyoD and MyoG and reference primer pairs. cDNA is obtained by extracting sample RNA and performing reverse transcription, and real-time fluorescent PCR is performed by using the provided primers, so that the mRNA expression amount of the pig muscle regulatory factors MyoD and MyoG can be simultaneously detected quickly, specifically, sensitively and stably, and the application can be used for detecting the change in the expression level of the regulatory factors before and after the differentiation of pig muscle stem cells, so that the differentiation condition of pig breeding meat can be judged.

The present invention relates generally to stable liquid formulations comprising polypeptides with 10Fn3 domains which bind to myostatin and unit dosage forms thereof for administration via various routes, including subcutaneous (SC), for treating muscle-wasting and metabolic disorders.

This disclosure relates to isolated oligonucleotides comprising duplex regions targeting human MSTN mRNA, delivery systems, kits, and compositions comprising the same, and methods of using the same for inhibiting or downregulating MSTN gene expression and treating or preventing a disease or disorder associated with aberrant or increased expression or activity of MSTN or a disease or disorder where MSTN plays a role.

This disclosure relates to antibodies that specifically bind to tropomyostatin and / or latent myostatin, and their uses.

The present invention relates to a novel therapeutic agent capable of treating muscle diseases, metabolic diseases, and bone diseases by simultaneously inhibiting the activin type II receptor and myostatin. Specifically, the invention relates to a bispecific protein comprising an anti-ActRII antibody and an anti-Myostatin antibody, and the use thereof. The simultaneous inhibition of the activin type II receptor and myostatin according to the present invention exhibits excellent effects of muscle growth and bone differentiation as well as weight loss; thus, it resolves the problem of muscle loss, which is a side effect of existing anti-obesity treatments, and can effectively improve various metabolic diseases. Therefore, the bispecific protein of the present invention can be utilized in various fields for the improvement and treatment of muscle diseases, metabolic diseases, and bone diseases.

This disclosure relates to methods and compositions for inhibiting expression and / or activity levels of nuclear receptor corepressor 1 (NC0R1) and / or myostatin (MSTN) to treat various diseases or disorders.

This disclosure relates to isolated oligonucleotides comprising duplex regions targeting human MSTN mRNA, delivery systems, kits, and compositions comprising the same, and methods of using the same for inhibiting or downregulating MSTN gene expression and treating or preventing a disease or disorder associated with aberrant or increased expression or activity of MSTN or a disease or disorder where MSTN plays a role.

The present invention relates to compounds and their use in the treatment of lesions, in tissue regeneration and / or tissue engineering. The compounds act as substrates for enzymes having transglutaminase activity and are suitable for their immobilization and / or attached therapeutic or diagnostic molecules on extracellular matrix (ECM) or synthetic ECM-derived materials, in particular for the immobilization of myostatin inhibitors.

This disclosure provides myostatin and activin A peptide immunogen constructs, compositions and methods for their use in, for example, maintaining and improving muscle physiology (e.g., increasing muscle mass, strength, function, tone or endurance), preventing and treating muscular or musculoskeletal injury, preventing and treating a disorder associated with muscle loss or insufficient muscle growth, and / or preventing and treating muscle wasting diseases.

Provided herein are oligonucleotides (e.g., siRNA) targeting MSTN. Also provided are methods of treating a disease associated with MSTN expression.

The present invention provides a complex comprising a molecular payload that modulates the expression or activity of genes involved in muscle growth and maintenance (e.g., MSTN, INHBA, and / or ACVR1B), and a muscle targeting agent covalently linked to such molecular payload. [Solution] A complex is provided comprising a muscle targeting agent covalently linked to a molecular payload that modulates the expression or activity of myostatin (MSTN), inhibin beta A (INHBA), and / or activin receptor type 1B (ACVR1B), wherein the muscle targeting agent specifically binds to an internalized cell surface receptor on muscle cells.

Provided herein are anti-myostatin antibodies which bind myostatin. The anti-myostatin antibodies of the disclosure are useful for the treatment of muscle dystrophies by blocking myostatin signaling. Also provided herein are methods of use of the anti-myostatin antibodies.

A myostatin (MSTN) protein mutant and a preparation method thereof are provided. The amino acid sequence of the mutant is any one of the sequences shown in SEQ ID NO. 15, SEQ ID NO. 17 or SEQ ID NO. 20. Under the guidance of specially designed single guide ribonucleic acid (sgRNA), a mutant in which the 281st and / or 282nd cysteine of the sheep myostatin full length protein containing the signal peptide is mutated into arginine is obtained through adenine base editor (ABE) editing, and the nucleotide sequence of the sgRNA is shown in SEQ ID NO. 5.

The present invention relates to antibodies, or antigen-binding fragments thereof, that specifically bind proMyostatin and / or latent Myostatin, and methods and uses thereof for treating metabolic diseases.